<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Peyre M</submitter><funding>French CRC</funding><funding>French national PHRC</funding><pagination>e16211</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11235986</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Nonreversible hearing loss (HL) is the main sequelae of Susac syndrome (SuS). We aimed to identify risk factors for HL in SuS.&lt;h4>Methods&lt;/h4>The CARESS study is a prospective national cohort study that started in December 2011, including all consecutive patients with SuS referred to the French reference center. The CARESS study was designed with a follow-up including fundoscopy, audiometry, and brain magnetic resonance imaging at 1, 3, 6, and 12 months after diagnosis and then annually for 5 years. The primary outcome was the occurrence at last follow-up of severe HL defined as the loss of 70 dB in at least one ear on audiometry or the need for hearing aids.&lt;h4>Results&lt;/h4>Thirty-six patients (female 66.7%, median age 37.5 [range 24.5-42.5] years) included in the clinic</pubmed_abstract><journal>European journal of neurology</journal><pubmed_title>Risk factors for severe hearing loss in Susac syndrome: A national cohort study.</pubmed_title><pmcid>PMC11235986</pmcid><funding_grant_id>P081261</funding_grant_id><funding_grant_id>CRC19059</funding_grant_id><pubmed_authors>Sacre K</pubmed_authors><pubmed_authors>French Susac Study Group</pubmed_authors><pubmed_authors>Halimi C</pubmed_authors><pubmed_authors>Turc G</pubmed_authors><pubmed_authors>Debruxelles S</pubmed_authors><pubmed_authors>Papo T</pubmed_authors><pubmed_authors>Capron J</pubmed_authors><pubmed_authors>Peyre M</pubmed_authors><pubmed_authors>Lapergue B</pubmed_authors><pubmed_authors>Mageau A</pubmed_authors><pubmed_authors>Mohamed S</pubmed_authors><pubmed_authors>Rouzaud D</pubmed_authors><pubmed_authors>de Brouker T</pubmed_authors><pubmed_authors>Henry Feugeas MC</pubmed_authors><pubmed_authors>Doan S</pubmed_authors><pubmed_authors>Hamidou M</pubmed_authors><pubmed_authors>Laouenan C</pubmed_authors><pubmed_authors>Francois C</pubmed_authors><pubmed_authors>Delory N</pubmed_authors><pubmed_authors>Godard-Ducceschi S</pubmed_authors><pubmed_authors>Grosset-Janin D</pubmed_authors><pubmed_authors>Le Quellec A</pubmed_authors><pubmed_authors>Mouthon L</pubmed_authors><pubmed_authors>Chauveheid MP</pubmed_authors><pubmed_authors>Goulenok T</pubmed_authors><pubmed_authors>Noury JB</pubmed_authors><pubmed_authors>Beldjoudi N</pubmed_authors><pubmed_authors>Klein I</pubmed_authors><pubmed_authors>Alexandra JF</pubmed_authors><pubmed_authors>Farhi F</pubmed_authors><pubmed_authors>Bodenant M</pubmed_authors><pubmed_authors>Godeau B</pubmed_authors><pubmed_authors>Aumaitre O</pubmed_authors><pubmed_authors>Wacongne A</pubmed_authors><pubmed_authors>de Bustos EM</pubmed_authors><pubmed_authors>Ellie E</pubmed_authors><pubmed_authors>Dossier A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk factors for severe hearing loss in Susac syndrome: A national cohort study.</name><description>&lt;h4>Background&lt;/h4>Nonreversible hearing loss (HL) is the main sequelae of Susac syndrome (SuS). We aimed to identify risk factors for HL in SuS.&lt;h4>Methods&lt;/h4>The CARESS study is a prospective national cohort study that started in December 2011, including all consecutive patients with SuS referred to the French reference center. The CARESS study was designed with a follow-up including fundoscopy, audiometry, and brain magnetic resonance imaging at 1, 3, 6, and 12 months after diagnosis and then annually for 5 years. The primary outcome was the occurrence at last follow-up of severe HL defined as the loss of 70 dB in at least one ear on audiometry or the need for hearing aids.&lt;h4>Results&lt;/h4>Thirty-six patients (female 66.7%, median age 37.5 [range 24.5-42.5] years) included in the clinic</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-02T22:12:52.301Z</modification><creation>2025-04-19T13:13:44.93Z</creation></dates><accession>S-EPMC11235986</accession><cross_references><pubmed>38235955</pubmed><doi>10.1111/ene.16211</doi></cross_references></HashMap>